| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Letters |
Central Clinical Laboratories, Department of Clinical Pathology, University Hospitals Leuven,, B-3000 Leuven, Belgium
a Address correspondence to this author at: Department of Clinical Pathology, UZ-K.U. Leuven Medical Center, B-3000 Leuven, Belgium. Fax 32-16-332896; e-mail jaak.billen{at}uz.kuleuven.ac.be %Editor's Note: A representative of the manufacturer declined the opportunity to reply.
To the Editor:
Recently, several new nonisotopic protein-binding folate assays have become available. We have studied the AxSYM folate assay (Abbott Laboratories, Abbott Park, IL), in which folate is quantified by measurement of unoccupied binding sites on the folate-binding protein (1). The calibrators for the assay cover the range 0–45 nmol/L.
In the absence of an internationally accepted reference method or material (2), we have compared the performance of the AxSYM method with two methods commonly used nationally and internationally, namely the SimulTrac-SNB (ICN Pharmaceuticals Inc.) and the Quantaphase II (Bio-Rad Laboratories). Both of these are competitive RIAs.
We selected 100 patient samples from among serum specimens received in the laboratory for determination of serum folate to obtain a concentration range up to 68 nmol/L (30 µg/L) as measured by the SimulTrac-SNB assay. The sera were frozen at -20 °C until analysis. After thawing, all three comparison assays were performed on the same day. Sample collection procedures were in agreement with the guidelines of the hospital's Ethical Commission.
Results by the two comparison methods agreed well, with
Passing–Bablok (3) analysis yielding the following
regression equation: y (Quantaphase II) = 0.93x
(SimulTrac) - 0.23 nmol/L; r = 0.942; n = 100. In
comparisons of the AxSYM assay with the two isotopic methods, the
regression plots (Fig. 1
, A and C) and the Bland–Altman (4) bias plots (Fig. 1
, B and D) suggested regression lines with three different slopes.
Above 23 nmol/L (10 µg/L) as measured by the comparison methods, the
AxSYM method produced a flat response. Linearity of the assays was
tested by mixing a very high (45 nmol/L) and a very low sample (1
nmol/L) to obtain increasing concentrations in steps of 10%. Each
mixture was tested in duplicate, and statistical evaluations were made
by linear regression analysis. The AxSYM method showed
significant nonlinearity (Fig. 1E
). The analogous plots for SimulTrac
and Quantaphase II were linear between 10% and 100% of high sample,
with r2 = 0.996 and
r2 = 0.999, respectively. The
measured/expected concentration was between 99% and 101% at the
highest values.
|
Although the manufacturer's product insert states that "some
samples in the upper region of the dynamic range may read lower in the
AxSYM assay when compared with some other commercial assays", our
data suggest that samples >23 nmol/L (the middle of the dynamic range)
routinely read lower in the AxSYM assay than in either of the two
widely used methods. In agreement with the manufacturer's warning that
"serum and plasma specimens from patients with renal impairment may
exhibit varying degrees of falsely depressed values", marked
disagreement was observed between the AxSYM and the comparison methods
for the serum specimens of chronic renal failure patients (indicated by
the numeral 1 in Fig. 1
).
Similar apparent limitations in the dynamic range of the AxSYM method appeared to be present when folate was measured in erythrocyte hemolysates. At concentrations >906 nmol/L (>400 µg/L) with the SimulTrac method and >453 nmol/L (>200 µg/L) with the Quantaphase II method, the regression lines were found to bend. We saw no erythrocyte folate results >1360 nmol/L (>600 µg/L) by the AxSYM method, even in patients known to be taking folate supplements regularly for a protracted period of time.
We conclude that the dynamic range of the AxSYM folate assay does not extend above 23 nmol/L (10 µg/L) for serum folate and not above 1360 nmol/L (600 µg/L) for erythrocyte folate. This is only half the dynamic range of other protein-binding folate assays.
References
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  D. H. Wilson, G. Williams, R. Herrmann, D. Wiesner, and P. Brookhart Issues in Immunoassay Standardization: The ARCHITECT Folate Model for Intermethod Harmonization Clin. Chem., April 1, 2005; 51(4): 684 - 687. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
